Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladostigil in mild to moderate probable Alzheimer's disease
2010-019858-41Phase 2Terminated
- Sponsor
- Avraham Pharmaceuticals Ltd.
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Ladostigil with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale. Started Sep 2010; status: terminated.
02
Drugs
ladostigil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-019858-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019858-41.